These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC). Parums DV Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327 [TBL] [Abstract][Full Text] [Related]
26. Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study. Mazzaschi G; Perrone F; Minari R; Verzè M; Azzoni C; Bottarelli L; Pluchino M; Armillotta MP; Ubaldi A; Altimari A; Gruppioni E; Sperandi F; Andrini E; Guaitoli G; Bettelli S; Longo L; Bertolini F; Barbieri F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Gnetti L; Tiseo M; Clin Lung Cancer; 2022 Nov; 23(7):e478-e488. PubMed ID: 36002369 [TBL] [Abstract][Full Text] [Related]
27. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice. Cho BC; Loong HHF; Tsai CM; Teo MLP; Kim HR; Lim SM; Jain S; Olsen S; Park K Curr Oncol; 2022 Mar; 29(3):2154-2164. PubMed ID: 35323374 [TBL] [Abstract][Full Text] [Related]
28. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients. Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754 [TBL] [Abstract][Full Text] [Related]
29. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation. Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531 [TBL] [Abstract][Full Text] [Related]
30. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110 [TBL] [Abstract][Full Text] [Related]
31. KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry. Isaksson J; Berglund A; Louie K; Willén L; Hamidian A; Edsjö A; Enlund F; Planck M; Vikström A; Johansson M; Hallqvist A; Wagenius G; Botling J Clin Lung Cancer; 2023 Sep; 24(6):507-518. PubMed ID: 37296038 [TBL] [Abstract][Full Text] [Related]
32. Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer. Crucitta S; Ruglioni M; Novi C; Manganiello M; Arici R; Petrini I; Pardini E; Cucchiara F; Marmorino F; Cremolini C; Fogli S; Danesi R; Del Re M Clin Chim Acta; 2023 Feb; 541():117239. PubMed ID: 36736684 [TBL] [Abstract][Full Text] [Related]
33. Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression. Sestokaite A; Gedvilaite V; Cicenas S; Sabaliauskaite R; Jarmalaite S Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108122 [TBL] [Abstract][Full Text] [Related]
34. Comparison of real-life data from patients with NGS panel negative and Gökyer A; Küçükarda A; Köstek O; Gökmen İ; Özcan E; Sayın S; Taştekin E; Hacıoğlu B; Erdoğan B; Uzunoğlu S; Çiçin İ Tumori; 2022 Apr; 108(2):141-146. PubMed ID: 33624577 [TBL] [Abstract][Full Text] [Related]
35. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology. Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T; Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746 [TBL] [Abstract][Full Text] [Related]
36. Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. Cui W; Franchini F; Alexander M; Officer A; Wong HL; IJzerman M; Desai J; Solomon BJ Lung Cancer; 2020 Aug; 146():310-317. PubMed ID: 32619782 [TBL] [Abstract][Full Text] [Related]
37. Performance of Idylla KRAS assay on extracted DNA and de-stained cytology smears: Can we rescue small sample? Wei Q; Eltoum IA; Mackinnon AC; Harada S Ann Diagn Pathol; 2022 Oct; 60():152023. PubMed ID: 35961282 [TBL] [Abstract][Full Text] [Related]
38. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. Santis G; Angell R; Nickless G; Quinn A; Herbert A; Cane P; Spicer J; Breen R; McLean E; Tobal K PLoS One; 2011; 6(9):e25191. PubMed ID: 21949883 [TBL] [Abstract][Full Text] [Related]
39. Rapid Somatic Mutation Testing in Colorectal Cancer by Use of a Fully Automated System and Single-Use Cartridge: A Comparison with Next-Generation Sequencing. Al-Turkmani MR; Godwin KN; Peterson JD; Tsongalis GJ J Appl Lab Med; 2018 Sep; 3(2):178-184. PubMed ID: 33636938 [TBL] [Abstract][Full Text] [Related]
40. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor. Serna-Blasco R; Sánchez-Herrero E; Sanz-Moreno S; Rodriguez-Festa A; García-Veros E; Casarrubios M; Sierra-Rodero B; Laza-Briviesca R; Cruz-Bermúdez A; Mielgo-Rubio X; Sánchez-Hernández A; Uribelarrea EA; Calvo V; Romero A; Provencio M ESMO Open; 2021 Oct; 6(5):100279. PubMed ID: 34607284 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]